Measles Vaccine

Measles vaccine

      &nbs; MMR is recommended for all children: first dose between 12 and 15 months and recalled 2 to 5 years later. The vaccine may cause mild clinical response approximately 8 days after vaccination: fever of 38 °, rash ... Like any fever, fever after the vaccine can cause febrile convulsions (1 case per 2 000 vaccinations). The vaccine is causing a mild inapparent infection which is not contagious and secretion (production) of antibodies comparable to natural measles. After administration of the vaccine, fever over 38 ° C is observed for 5 to 15 days in less than 5% of vaccinees, and is usually accompanied by a rash. There may be very rarely, a reaction of the central nervous system.

      &nbs; The use of immunoglobulin (antibody) is sometimes useful in pregnant patients and children under 1 year. Immune globulin must then be administered within 2 days of contagion in susceptible individuals exposed. In children under 1 year and pregnant women, specific immunoglobulins against measles or polyvalent human immunoglobulin can be administered intramuscularly immediately. This administration does not prevent vaccination within 5 to 6 months. It is strictly recommended to involve a simultaneous administration of specific immunoglobulin and human polyvalent immunoglobulins. There are cases where the administration of measles vaccine should not be done. In cases of generalized malignancies as leukemia or lymphoma or immunosuppressive diseases, patients are undergoing treatment with cortisone, irradiation, or alkylating agents with a therapeutic regimen including antimetabolites. Vaccination should not be performed during pregnancy or in cases of untreated tuberculosis or in patients with immunosuppression.

      &nbs; The injection of the vaccine is combined with that of rubella and mumps. This vaccine R.O.R. is administered after the age of 1 year or sooner if the child lives in the community. In children and infants infected with human immunodeficiency virus (AIDS), medical advocates the use of live vaccine against measles. However, it is necessary that these children are not severely immunocompromised, as there is a risk of subsequent measles vaccination.